What Is Hexarelin? Mechanism, GH Axis & Cardiac Evidence

TL;DR: Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide growth hormone secretagogue (GHRP) and potent GHS-R1a agonist studied in animal models and limited human pharmacology trials for pulsatile GH release. Uniquely among synthetic GHRPs, hexarelin has also been studied for cardiovascular effects mediated independently of GH release, through binding to the cardiac scavenger receptor CD36. Hexarelin is not FDA approved for any human use and is classified by WADA as prohibited under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics).

Research-Use Disclaimer: This article is for educational and research reference purposes only. Hexarelin is a research compound, not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical research or limited human pharmacology studies. For adults 21+ with a research interest only.

What Is Hexarelin? Definition and Structure

Hexarelin is a synthetic hexapeptide belonging to the growth hormone secretagogue (GHS) class, a family of compounds that stimulate GH release by activating the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the endogenous hormone ghrelin. Its amino acid sequence is His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2, incorporating a D-amino acid and a methylated tryptophan residue that contribute to its metabolic stability and receptor binding potency.

Hexarelin belongs to the growth hormone-releasing peptide (GHRP) subfamily, which includes GHRP-6, GHRP-2, and ipamorelin. Unlike GHRH (growth hormone-releasing hormone), which stimulates GH via its own distinct receptor, hexarelin and other GHRPs act through the GHS-R1a receptor, a G protein-coupled receptor cloned from pituitary and hypothalamic tissue. A landmark 1997 review by Ghigo et al., published in the European Journal of Endocrinology, systematically documented that hexarelin and related GHRPs produce marked, dose-related GH-releasing activity after intravenous, subcutaneous, intranasal, and oral administration in both animals and humans, with a GH-releasing effect synergistic with GHRH.

How Does Hexarelin Work? Two Documented Receptor Pathways

Hexarelin’s preclinical pharmacology is unusual in that it operates through two structurally unrelated receptors, documented in the peer-reviewed literature: the canonical GHS-R1a pathway responsible for GH release, and the CD36 pathway associated with cardiovascular effects that are independent of GH.

Pathway 1: GHS-R1a Agonism and GH Release

The primary documented mechanism of hexarelin is agonism at GHS-R1a, a Gq/11-coupled G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary and in the hypothalamus. Activation of GHS-R1a by hexarelin triggers intracellular signaling cascades resulting in pulsatile GH secretion. This mechanism is shared with other GHRPs and with ghrelin, but hexarelin exhibits substantially higher binding potency.

In a 2000 study by Papotti et al. published in the Journal of Clinical Endocrinology & Metabolism, researchers used a radiolabeled hexarelin analog ([¹²⁵I]Tyr-Ala-hexarelin) to map GHS receptor binding sites across a wide panel of human tissues. The study found that GHS receptor binding was detected most prominently in the myocardium, followed by adrenal, gonads, arteries, lung, liver, skeletal muscle, kidney, and pituitary, and crucially, that in non-endocrine tissues such as the heart, ghrelin and MK-0677 were substantially less potent than hexarelin at displacing the radioligand, suggesting a distinct receptor subtype or binding site. This study provided the first comprehensive tissue-distribution map for GHS receptors using hexarelin as the reference ligand.

A 2004 study by Bresciani et al., published in Neuroendocrinology, investigated whether hexarelin regulates expression of its own receptor at pituitary and hypothalamic sites. The study found that hexarelin treatment significantly upregulated GHS-R1a mRNA levels at both the pituitary and hypothalamus in infant rats, with the effect being age-dependent, present in 10-day-old animals but not in young adults under normal conditions. This receptor auto-regulation adds a layer of complexity to GHS-R1a pharmacology that distinguishes hexarelin from simpler agonist-receptor interactions.

Pathway 2: CD36, A Non-GH Cardiac Receptor

CD36 is a multifunctional scavenger receptor expressed in cardiac muscle, vascular endothelium, macrophages, and adipose tissue, where it participates in fatty acid uptake, lipid metabolism, and inflammatory signaling. Research published from the early 2000s onward documented that hexarelin, but not ghrelin, binds to CD36 in cardiac tissue with functional consequences distinct from GHS-R1a activation.

The significance of this distinction was established by Torsello et al. in a 2003 study published in Endocrinology. This study compared hexarelin and ghrelin in hypophysectomized rats subjected to ischemia-reperfusion (I/R) injury using an isolated heart model. The key finding: hexarelin was far more effective than ghrelin at preventing ischemia-reperfusion damage, providing 60% protection against elevated left ventricular end-diastolic pressure compared to 15% for ghrelin, and that passive immunization against ghrelin did not worsen I/R damage, indicating that endogenous ghrelin plays a minor role in physiological cardiac protection. The study concluded that hexarelin’s cardiac effects are mediated in part by GHS-R1a and largely by interactions with CD36.

A 2014 review by Mao, Tokudome, and Kishimoto in the Journal of Geriatric Cardiology synthesized the accumulated evidence on this dual-pathway biology. The review documented that hexarelin binds CD36 in the heart and blood vessels to mediate cardioprotective effects, and noted that hexarelin is chemically more stable and functionally more potent than ghrelin when studied in preclinical cardiovascular models. The reviewers proposed this dual-receptor profile as a mechanistic basis for cardiovascular research interest in hexarelin.

What Does the Research Show? Evidence by Tier

Tier 1: Human Pharmacology Data (Limited)

Human data for hexarelin exists in the form of pharmacology studies rather than efficacy trials. A 1995 clinical study by Massoud, Hindmarsh, and Brook, published in Clinical Endocrinology, enrolled six healthy adult male subjects and compared the GH-releasing effects of hexarelin and GHRH under controlled intravenous conditions. The study found that the peak serum GH response to hexarelin was greater than that to GHRH, and that prior administration of exogenous rhGH partially suppressed hexarelin’s GH-releasing activity, indicating feedback sensitivity and providing evidence that hexarelin operates through a mechanism amenable to endogenous GH regulation. The study classified hexarelin as “a potent GH secretagogue” in humans, while noting that the precise mechanism remained under investigation. This represents human pharmacokinetic/pharmacodynamic evidence, not a clinical efficacy or safety trial, and does not establish therapeutic utility.

The 1997 GHRP review by Ghigo et al. in the European Journal of Endocrinology further synthesized available human data for the GHRP class including hexarelin, documenting age-related variation in GH-releasing response (highest at puberty, declining with age), synergy with GHRH, partial desensitization under continuous infusion, and preserved activity in certain GH hyposecretory states. As with the Massoud et al. study, these are pharmacology observations, not therapeutic efficacy data from randomized controlled trials.

Tier 2: Preclinical Animal Studies (Multiple, Peer-Reviewed)

The majority of hexarelin’s documented evidence base resides in well-designed preclinical studies across cardiovascular, neuroendocrine, and CNS research contexts.

In cardiovascular models, the 2017 study by Huang et al. in the International Heart Journal investigated hexarelin in an in vivo rat ischemia-reperfusion model, finding that hexarelin-treated animals showed improved cardiac systolic function, decreased malondialdehyde production, and increased surviving cardiomyocyte counts compared to controls following left coronary artery ligation and reperfusion. The study further characterized the mechanism as involving modification of the interleukin-1 (IL-1) signaling pathway through activation of cardiac GHSR1a receptors, with the GHSR antagonist [D-Lys3]-GHRP-6 blocking the beneficial effect. The beneficial effects of hexarelin were described as slightly superior to equimolar ghrelin in this model.

A broader 2015 review by Mosa et al. published in Endocrine examined ghrelin and hexarelin in the context of diabetes and cardiometabolic research, documenting that hexarelin has been shown to regulate peroxisome proliferator-activated receptor gamma (PPAR-γ) in macrophages and adipocytes, potentially connecting its CD36-mediated activity to lipid metabolism and insulin sensitization pathways in preclinical models. The review positioned hexarelin within the broader framework of GH-independent GHS biology with implications for metabolic and cardiovascular research.

In neurological research contexts, a 2009 study by Barlind et al. in Growth Hormone & IGF Research investigated hexarelin’s effects on hippocampal neurogenesis in a mouse model of radiation-induced brain injury. The study found that hexarelin treatment significantly increased the number of BrdU-positive proliferating cells in the granule cell layer of the dentate gyrus by approximately 50% compared to irradiated controls, consistent with GHS-R1a’s documented expression in hippocampal regions and suggesting a role in neural progenitor cell biology in this model. The authors characterized this as partial restoration of the irradiation-depleted proliferating cell pool.

Receptor Pharmacology: Somatostatin and Cortistatin Cross-Reactivity

A 2001 study by Deghenghi et al. published in the Journal of Endocrinological Investigation used [¹²⁵I]Tyr-Ala-hexarelin as a radioligand to probe competitive binding at human pituitary GHS-R. The study established that cortistatin-14, a neuropeptide with structural homology to somatostatin, bound to GHS-R in human pituitary tissue and fully displaced hexarelin from its binding site, while somatostatin itself and its fragments did not. Hexarelin displaced the radioligand with approximately four orders of magnitude greater affinity than ghrelin or cortistatin. This study defined hexarelin’s pharmacological relationship with endogenous GHS-R-interacting peptides and underscored the receptor’s complexity as a target with multiple potential endogenous modulators.

What Is Hexarelin’s Evidence Tier? An Honest Assessment

Accurately representing hexarelin’s evidence base requires distinguishing its well-characterized receptor pharmacology and preclinical cardiovascular data from the much thinner body of human clinical evidence. The table below summarizes the landscape as documented in peer-reviewed literature.

The critical limitation to state plainly: hexarelin’s two-pathway biology, GHS-R1a for GH release and CD36 for cardiovascular effects, is documented in preclinical models and receptor-binding studies, not in human clinical trials. The degree to which these preclinical findings translate to human physiology remains scientifically unestablished. The human pharmacology data confirms GH-releasing activity in healthy male volunteers but does not address cardiovascular endpoints, longer-term safety, or therapeutic efficacy for any indication. No large, placebo-controlled human RCTs have been published as of 2026.

What Is Hexarelin’s Regulatory and Anti-Doping Status?

FDA (United States)

Hexarelin is not approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. It has no approved indication, no authorized human dosing protocol, and is not available through lawful commercial channels as a therapeutic agent. Researchers should consult current FDA guidance directly regarding its regulatory classification.

WADA (World Anti-Doping Agency)

Growth hormone secretagogues, including hexarelin, are classified under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics on the WADA Prohibited List. S2 covers all GH-releasing peptides and peptidomimetics, prohibited both in-competition and out-of-competition. Athletes subject to WADA rules are prohibited from using hexarelin in any context, including in animal research settings associated with sport. GH secretagogue detection methodology is actively developed; researchers designing doping control studies should consult the current WADA Technical Document for hexarelin’s detection status.

Frequently Asked Questions About Hexarelin

What is hexarelin and how does it work?

Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide growth hormone secretagogue that acts as a potent agonist at the GHS-R1a receptor, stimulating pulsatile GH release from the anterior pituitary. In addition to GHS-R1a, preclinical research has identified CD36, a scavenger receptor expressed in cardiac tissue, as a second binding site mediating cardiovascular effects that are independent of GH release. Both pathways are documented in peer-reviewed animal model and receptor-binding studies.

Is hexarelin FDA approved?

No. Hexarelin is not approved by the FDA for any therapeutic use in humans. It is a research compound studied in preclinical animal models and limited human pharmacology studies. It has no approved indication, no authorized human dosing protocol, and is not legally available as a prescription drug or dietary supplement in the United States.

Is hexarelin prohibited by WADA?

Yes. The WADA Prohibited List classifies growth hormone secretagogues, including hexarelin, under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. The prohibition applies both in-competition and out-of-competition for all athletes subject to WADA rules.

What is the difference between hexarelin and ghrelin?

Ghrelin is the endogenous 28-amino acid ligand of GHS-R1a, produced primarily in the stomach. Hexarelin is a shorter synthetic hexapeptide designed to activate the same receptor with greater potency. A 2003 study published in Endocrinology (Torsello et al., PMID 12697684) found that hexarelin was substantially more cardioprotective than ghrelin in an isolated rat heart I/R model and that hexarelin’s cardiac effects are mediated in part through CD36, a pathway ghrelin does not substantially activate. This mechanistic distinction makes hexarelin a unique research tool for separating GHS-R1a-dependent from GHS-R1a-independent GHS effects.

For educational and research reference purposes only. Not medical advice. Not for human use.